Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765179 alone and with ezabenlimab or pembrolizumab in advanced solid tumors and head and neck cancer
NL-OMON60606Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765179, ezabenlimab and pembrolizumab in Nonhematologic neoplasms and head and neck cancer (HNC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint(s). Started Aug 2022; status: active, not recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmshead and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON60606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60606.